Literature DB >> 2788504

Some theoretical and practical limitations of interleukin-2. Ten cases of advanced breast cancer treated with continuous infusion of IL-2.

L Israel1, V Cour, I Pihan, J F Morere, J L Breau, C R Franks, P Palmer, E Loriaux.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2788504     DOI： 10.1016/0305-7372(89)90038-8

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


× No keyword cloud information.
  3 in total

1.  Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.

Authors:  Svetlana G Semushina; Dmitry A Aronov; Ekaterina V Moiseeva
Journal:  Pathol Oncol Res       Date:  2018-03-06       Impact factor: 3.201

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Low-dose recombinant interleukin-2 and low-dose cyclophosphamide in metastatic breast cancer.

Authors:  D V Spicer; A Kelley; R Herman; G Dean; L Stevenson; M S Mitchell
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.